Hospitalizations Due to ADRs and Drug Interactions

• Chart review of HIV admissions to a Canadian hospital: Pre-HAART Post-HAART

(04/95-03/96) (08/96-08/97)

# ADRs 89/436 (20.4%) 69/323 (21.4%)

# interactions 12/436 (2.5%) 7/323 (2.2%)

• pre-HAART: azole, AZT/ganciclovir interactions
• post-HAART: PI interactions (85.7%)

[Foisy et al. CJID 2000;11:193-201]

Previous slide

Next slide

Back to first slide

View graphic version

Foisy MM, Gough K, Quan C, Harris K, Ibanez D, Phillips A.

Hospitalization due to adverse drug reactions and drug interactions before and after highly active antiretroviral therapy. Can J Inf Dis 2000;11(4):193-201.

****

Two large retrospective chart reviews of inpatients receiving a protease inhibitor showed that approximately 50% were receiving at least 1 other drug that could potentially result in a drug interaction.[2,3] These data highlight the importance of prospective monitoring for drug interactions in patients receiving protease inhibitors. The rate was increased in patients with more advanced disease (lower CD4+ cell counts)[2] and approximately half of the drug interactions were deemed to be potentially serious or life-threatening.[3]

van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 1997; 17: 774-8 Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS 1998; 12: 228-30